Invest

Partner with us to advance groundbreaking solutions in pain and addiction treatment while driving long-term value.

Phoenix has received strong validation of its science from the NIH and the DoD, which together awarded the company grants of more than $12 million to fund the advancement of its compounds. Grant funds have been supplemented with approximately $10 million of private equity investment including a $2 million online public offering of private securities that were oversubscribed under SEC Rule CF. The company is currently applying for additional grants as well as raising funds through private equity investment to fund the further advancement of its compounds.

Reasons to Invest

  • Three shots on goal: pain, addiction & PTSD/AUD
  • Large & growing $30B+ unmet medical need: The Opioid crisis
  • Robust IP 
  • Deeply experienced team
  • Acquisition or out-license exit: 2027 / 2028
  • “Bench” of 25 additional drug candidates
  • Significant past and present non-dilutive funding with strong validation of the science and the team by the NIH and the DOD.
  • Government, industry, and the medical field have great ethical and financial motivation to see the opioid problem solved
  • PPL-138 has been studied at multiple universities and research institutions.

Investment Opportunities

Go to Top